• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    Viatris To Release Q1 2026 Financial Results On May 7

    PR NEWSWIRE

    Viatris Presents Data At 2026 Ascrs Annual Meeting

    PR NEWSWIRE

    Viatris Advances Innovative Portfolio with Approval of Effexor

    PR NEWSWIRE

    Viatris Outlines 2030 Vision for Revenue, Earnings Growth

    PR NEWSWIRE

    GoodRx, Viatris Partner To Provide Up To 85% Savings On Brand

    PHARMIWEB

    EU Court Rejects Industry Bid to Annul Wastewater Directive

    RAPS

    Blinkrx Appoints Ex-Senator Joe Manchin, Heather Manchin

    PHARMIWEB

    BlinkRx Appoints Ex-Senator Joe Manchin, Heather Manchin

    BUSINESSWIRE

    Viatris to Present 2025 Financial Results on Feb. 26, 2026

    PR NEWSWIRE

    Viatris Appoints Matthew J. Maletta As Chief Legal Officer

    PR NEWSWIRE

    Viatris Launches Inpefa to Expand Heart Failure Portfolio

    PR NEWSWIRE

    Viatris Launches Inpefa for Heart Failure Treatment

    PR NEWSWIRE

    Viatris Names Ramsburg Chief People & Corporate Affairs Officer

    PR NEWSWIRE

    Viatris Provides Pipeline Update On Four Regulatory Milestones

    PR NEWSWIRE

    Viatris To Present At J.P. Morgan Healthcare Conference

    PR NEWSWIRE

    Viatris To Participate In Upcoming Investor Conferences

    PR NEWSWIRE

    Viatris Named Among Fortune`s Best Global Workplaces 2025

    PR NEWSWIRE

    Viatris Updates 2025 Financial Guidance After Q3 Results

    PR NEWSWIRE

    Viatris Announces Quarterly Dividend

    PR NEWSWIRE

    Viatris Completes Acquisition of Aculys Pharma

    PR NEWSWIRE

    Viatris To Participate In Upcoming Investor Conferences

    PR NEWSWIRE

    Viatris Makes Forbes` World`s Best Employers List 5Th Year in Row

    PR NEWSWIRE

    Viatris To Release Q3 2025 Financial Results On Nov 6, 2025

    PR NEWSWIRE

    Viatris Names Andrew as Chief Admin and Transformation Officer

    PR NEWSWIRE

    Viatris Reports Q2 2025 Results, Reaffirms 2025 Financial

    PR NEWSWIRE

    Viatris appoints David Simmons to its Board of Directors

    PR NEWSWIRE

    Viatris Announces Quarterly Dividend

    PR NEWSWIRE

    Viatris Presents Five Data on Fast-Acting Meloxicam at Pain Week

    PR NEWSWIRE

    Viatris Updates on Phase 3 Study of MR-139 for Blepharitis

    PR NEWSWIRE

    Viatris to Report Q2 2025 Financial Results on August 7, 2025

    PR NEWSWIRE

    Viatris Reports Positive Ph3 LYNX-2 Results In Visual Disturbance

    PR NEWSWIRE

    Viatris to Participate in Upcoming Investor Conferences

    PR NEWSWIRE

    Viatris Reports Positive 2 Ph 3 Studies Results for Meloxicam

    PR NEWSWIRE

    Viatris reports positive Phase 3 results for XULANE LO patch

    PR NEWSWIRE

    Viatris Appoints Frank D`Amelio and Michael Severino to Board

    PR NEWSWIRE

    Viatris to Present at BofA Securities 2025 Healthcare Conference

    PR NEWSWIRE

    Viatris Files Supplemental Drug Applications in Japan for Effexor

    PR NEWSWIRE

    Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

    PR NEWSWIRE

    Viatris to pay up to $335 M to resolve opioid-related claims

    REUTERS

    Viatris to Report Q1 2025 Financial Results on May 8, 2025

    PR NEWSWIRE

    Viatris to Present at Barclays Global Healthcare Conference

    PR NEWSWIRE

    Viatris Reports Fourth Quarter and Full Year 2024

    PR NEWSWIRE

    Nxera Assigns Japan, APAC Rights For Cenerimod To Viatris

    GLOBENEWSWIRE

    Idorsia, Viatris update collaboration for selatogrel, cenerimod

    GLOBENEWSWIRE

    Pfizer Partners with Mylan to Boost Ativan & Pacitane Sales

    INDIAINFOLINE

    Viatris to Report Q4 & Full Year 2024 Financial Results on Feb 27

    PR NEWSWIRE

    Viatris to Present at 43rd Annual J.P. Morgan Conference

    PR NEWSWIRE

    Viatris Publishes Phase 2b CARE Study Data for Cenerimod

    PR NEWSWIRE

    UK Watchdog Fines Viatris $1.9M Over Rule Breach In Theramex Probe

    REUTERS

    Viatris fined in Morocco over merger notification, sources say

    REUTERS

    Safecor Health Acquires Viatris` US Unit-Dose Packaging Business

    PR NEWSWIRE

    Viatris Reports Q3 Financial Results for 2024

    PR NEWSWIRE

    Viatris Announces Q32024 Dividend

    PR NEWSWIRE

    Viatris Announces Licenses Sotagliflozin Outside U.S. And Europe

    PR NEWSWIRE

    Lexicon Announces Licensing Agreement With Viatris For Sotagliflozin

    GLOBENEWSWIRE

    Viatris lays out $25M to tackle marketing of Lexicon`s Inpefa

    FIERCE PHARMA

    Viatris Reports Positive Results From Phase 3 Study In Japan

    PR NEWSWIRE

    Viatris Announces the Pricing Terms of Maximum Tender Offer

    PR NEWSWIRE

    Viatris Announces Early Tender Results And Increase In Pending Tender Offer

    PR NEWSWIRE

    Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.